Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product...(ction capacity for Zingo while re...)

reducing the manufacturing cost of goods for the product at minimal

additional capital expense.

Commercial quantities of Zingo, which was approved by the FDA in August, are expected to be available in the second quarter of 2008. Today's briefing reviewing Anesiva's commercialization plans will be webcast and may be found at http://www.anesiva.com In addition to the live webcast, a replay will be available.

"Blood draws and intravenous access procedures are a huge source of anxiety and stress for children and their parents. Despite published guidelines calling for the use of topical local anesthetics during these procedures, currently existing topical anesthetic creams and patches are not routinely used because they take 20 minutes or longer to act," stated William T. Zempsky, M.D., associate professor, Department of Pediatrics, University of Connecticut; associate director, Pain Relief Program, Connecticut Children's Medical Center, Hartford. "Zingo's rapid onset means that it can be easily incorporated into a medical procedure allowing uninterrupted care, an important advantage over current options." Dr. Zempsky will be the featured speaker at today's briefing.

"We are very excited about the prospects for Zingo, given its outstanding profile and the significant interest we have received from the public and from the medical community since the product received early FDA approval in August," stated John P. McLaughlin, chief executive officer of Anesiva. "We are maximizing the time until product availability with significant efforts to build advocacy and making the need to treat IV pain top of mind among targeted customers. This is intended to expedite Zingo's acceptance on hospital formularies and drive routine use. The collaboration we are announcing today with Sagent will support these efforts by enabling us to rapidly ramp up sales and ultimately
'/>"/>